2020 Endocrine Fellows Series: Type 1 Diabetes Care and Management
2020 Endocrine Fellows Series: Type 1 Diabetes Care and Management
Due to a technical glitch tied to the pre- and post-quizzes that resulted in incorrect scoring, we have reset both quizzes to resolve this issue. Unfortunately we had to remove any quiz attempts prior to June 25, so the quizzes must be completed again to be marked as complete. We apologize for the inconvenience.
T1D care and management is more than monitoring A1c. Access timely education and resources to adjust insulin therapy, select and use technologies, and prevent common complications through this self-paced multi-module course, Endocrine Fellows Series: Type 1 Diabetes Care and Management.
Looking for more information on diabetes devices? Here are device demonstrations provided by at ENDO Online.
This education activity is supported by an independent medical educational grant from Abbott Diabetes Care, Inc., Dexcom, Inc., Helmsley Charitable Trust, Insulet Corporation, Lilly USA LLC, Medtronic Diabetes, and Novo Nordisk Inc., Tandem Diabetes Care
If you have reached this product after watching the session recordings from ENDO Online, you only need to complete the following course items:
- Pre-course quiz
- Post-course quiz
This continuing medical education activity should be of substantial interest to pediatric and adult endocrine fellows of substantial interest to pediatric and adult endocrine fellows and other health care providers that treat patients with type 1 diabetes.
Upon completion of this educational activity, participants will be able to (or better able to):
- Discuss the prevalence, pathophysiology, and progression of T1D to recognize signs and differentially diagnose diabetes
- Devise individualized treatment strategies that use new and emerging insulin and non-insulin therapies to manage individuals with T1D with and without common comorbid conditions
- Incorporate diabetes technologies, including insulin pump therapy and continuous glucose monitoring, into treatment strategies for appropriate individuals with T1D and evaluate data from those technologies
- Recognize and evaluate individuals with T1D for signs of depression and distress using updated guidelines and practice tools
- Apply updated knowledge of treatments, practice guidelines, and clinical skills to improve care, long-term outcomes, and sick day management of individuals with T1D
Irl B. Hirsch, MD, University of Washington School of Medicine
Davida F. Kruger, MSN, APN-BC, BC-ADM, Henry Ford Health System
Ana Ramirez Berlioz, MD, University of Missouri-Columbia
Luisa Duran, MD, John Muir Health
Robert H. Eckel, MD, University of Colorado
Alison B. Evert, MS, RD, CDE, University of Washington
David M. Harlan, MD, UMass Memorial Medical Center – University Campus
Janet B. McGill, MD, MA, FACE, Washington University in St. Louis
Michael C. Riddell, PhD, York University
Elizabeth Seaquist, MD, University of Minnesota
Linda M. Siminerio, RN, PhD, CDE, University of Pittsburgh
Jill A. Weissberg-Benchell, PhD, CDE, Northwestern University
Jenise C. Wong, MD, PhD, University of California-San Francisco
STATEMENT OF INDEPENDENCE
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.The presentation by guest keynote speaker, Kelly L. Close, MBA, is not CME-certified and disclosures not listed here.
The following faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Robert H. Eckel, MD, has served as a consultant and/or advisory board member to Amgen, Kowa American Corp., Novo Nordisk, and Sanofi and Regeneron Pharmaceuticals..
David M. Harlan, MD, serves as co-founder, president, and Chief Medical Officer of Stability Health, LLC.
Irl B. Hirsch, MD, has served as a consultant to Abbott Diabetes Care; Bigfoot Biomedical, Inc.; and Roche; and has received research support from Insulet Corporation and Medtronic Diabetes.
Davida F. Kruger, MSN, APN-BC, BC-ADM, has served on advisory boards and/or speaker bureaus for Abbott Diabetes Care, AstraZeneca, BI/Lilly, Dexcom, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Insulet Corporation, Intarcia Therapeutics, Inc., Novo Nordisk, sanofi-aventis U.S. LLC, and Valeritas, Inc.; and her institution has received research support from Abbott Diabetes Care, AstraZeneca, Dexcom, Eli Lilly and Company, Lexicon Pharmaceuticals, Inc., and Novo Nordisk.
Janet B. McGill MD, MA, has received grants to her institution from Dexcom, Medtronic, and Novo Nordisk; has served as a consultant for Aegerion, Bayer, Boehringer Ingelheim, Dexcom, Lilly, Metavant, Novo Nordisk, and Valeritas; and has served as a speaker for Aegerion, Dexcom, and Janssen.
Michael C. Riddell, PhD, has served as an advisory board member and/or speaker for Ascensia Diabetes Care, Dexcom, Insulet Corporation, Lilly Innovation, Medtronic, Xeris Pharmaceuticals, and Zucara Therapeutics; received grant support from Insulet Corporation; and received research support from Novo Nordisk and Sanofi.
Elizabeth Seaquist, MD, has received research support from Eli Lilly and Company; has served as an advisor to Eli Lilly; has served as a consultant to Eli Lilly, MannKind, Sanofi, and Zucara; and has served as a member of the International Hypoglycemia Study Group supported by Novo Nordisk Inc.
Linda M. Siminerio, RN, PhD, CDE, has received research support from Becton Dickinson.
Jenise C. Wong, MD, PhD, has received research support from Dexcom and served as a member of an advisory board for Tidepool.
The following faculty reported no relevant financial relationship: Luisa Duran, MD, Alison B. Evert, MS, RD, CDE, Ana Ramirez Berlioz, MD, and Jill A. Weissberg-Benchell, PhD, CDE.
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.
Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this recorded activity for a maximum of 10.0 AMA PRA Category 1 Credits™. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to a maximum of 10.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 10.00 ABIM MOC
- 10.00 AMA PRA Category 1 Credits™
- 10.00 CME Certificate of Participation